Small‐molecule inhibitors, such as BRAF and EGFR inhibitors (Bedard et al, 2020), and immune checkpoint inhibitors (CPI), such as anti‐PD‐1/L1 and anti‐CTLA‐4 (Waldman et al, 2020), have revolutionised cancer therapy (Chen et al, 2019). The gene discussed is EGFR; the disease is cancer.